| |
SPECTRUM OF CD
|
|---|
| |
ACD
|
GFD
|
RCDI
|
RCDII
|
EATL
|
|---|
| |
(n = 26)
|
(n = 26)
|
(n = 12)
|
(n = 16)
|
(n = 12)
|
|---|
|
Age at CD (yr)
|
Median, (SD;range)
|
42.5
|
45
|
50.5
|
61.5
|
61.5
|
|
(16; 21-76)
|
( 15; 21-77)
|
(16; 19-69)
|
(13; 27-74)
|
(7; 48-66)
|
|
Age at RCD
|
Median, (SD;range)
|
-
|
-
|
59
|
65
|
64
|
|
(11.5; 35-74)
|
(10; 47-77)
|
(8; 51-72)
|
|
Age at EATL
|
Median, (SD;range)
|
-
|
-
|
-
|
-
|
65
|
|
(6; 51-74)
|
|
HLA-staus
|
DQ2 heterozygous
|
10
|
7
|
8
|
7
|
3
|
|
DQ8 heterozygous
|
9
|
13
| | |
3
|
|
DQ2/8 heterozygous
|
3
|
2
|
1
|
3
|
2
|
|
DQ2 homozygous
|
4
|
4
|
3
|
6
|
4
|
|
Marsh
|
0
| |
12
| | |
2
|
|
I
| |
4
| | | |
|
II
| | | | |
1
|
|
IIIA
|
11
| |
8
|
9
|
5
|
|
IIIB
|
5
| |
3
|
4
|
3
|
|
IIIC
|
10
| |
1
|
3
|
1
|
|
ND
| |
10
| | | |
|
EMA
|
Negative (-)
| |
26
|
12
|
15
|
7
|
|
Dubious (+/-)
| | | |
1
|
2
|
|
Weak positive (+)
|
3
| | | | |
|
Positive (++)
|
11
| | | |
0
|
|
Stronglypositive(+++)
|
11
| | | |
2
|
|
ND
|
1
| | | |
1
|
|
TGA
|
Negative
| |
7
|
12
|
14
|
6
|
|
Dubious
| | | |
2
|
2
|
|
Weak positive
|
8
| | | |
1
|
|
Positive
|
6
| | | |
1
|
|
Strongly positive
|
9
| | | |
1
|
|
ND
|
3
|
19
| | |
1
|
|
Aberrant IELs (%)
|
Mean (SD;range)
|
-
|
-
|
4,0
|
64
|
7
|
|
(6.0; 2-19)
|
(23; 20-96)
|
(32; 1-87)
|
|
EATL type
|
Primary
|
-
|
-
|
-
|
-
|
4
|
| |
Secondary
| | | | |
8
|
-
ACD: active coeliac disease patients; GFD: coeliac disease patients on a gluten-free diet; RCDI and II: refractory coeliac disease type I and II; EATL: enteropathy associated T-cell lymphoma; EMA-A: endomysial antibodies; tTGA-A: tissue transglutaminase antibodies; IELs: intra-epithelial lymphocytes.
